IL17A and asthma: In this mouse model, the reduction of non-Th2 relevant endpoints (pulmonary neutrophilia and IL-8) and Th17 relevant endpoints (IL-17) observed with BIX119 was not achieved to the same extent by other launched and pipeline treatments for severe asthma (anti-IgE, anti-IL-5, anti-IL-4R, anti-TSLP, anti-IL-33 antibodies, monteleukast or oral corticosteroids; Table 2).